The panel comprised intestinal as well as pancreatobiliary differentiation markers (CK20, CDX2, MUC2, MUC1, MUC5AC), all of which are included in the classical transcriptional profile [2], a pancreatobiliary marker specific to the basal-like profile (CK17), general markers for PDAC cells (CK7, MUC6) and tumor-specific glycoproteins (CA19-9, CA125, and CEA), together with Ki67 to assess proliferation. The gene discussed is CDX2; the disease is neoplasm.